(Note: This is an IPO of units of securities of HeartBeam, Inc. Each unit consists of (a) one share of our common stock and (b) one warrant to buy one share of our common stock. The shares of our Common Stock and the Warrants are immediately separable and will be issued separately but will be purchased together in this offering. We anticipate that the initial public offering price per Unit will be between $5.50 and $6.50 per Unit. The proposed symbols are “BEAT” for the common stock and “BEATW” for the warrant. Both the stock and the warrants will trade on the NASDAQ.)

We are a medical technology company primarily focusing on telemedicine solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. Our aim is to deliver innovative, remote diagnostic and monitoring technologies that can be used for patients anywhere, with initial offerings for ambulatory and emergency room use. Our products require FDA clearance and have not been cleared for marketing. We believe our products and services will benefit many stakeholders, including patients, healthcare providers, and healthcare payors. Our initial focus is providing diagnostic data to help physicians with care management of patients with cardiovascular disease.

There are two major markets for our initial products: remote patient monitoring and the hospital Emergency Room (ER). First, we are developing our telehealth product to address the rapidly growing field of remote patient monitoring. Our telehealth product is comprised of a credit card-sized ECG machine and a powerful cloud-based diagnostic software expert system. We believe that we are uniquely positioned to play a central role in remote monitoring of high-risk coronary artery disease patients, because the studies performed so far have shown that our ischemia detection system is highly accurate. Our powerful ischemia detection system is unlike other ambulatory cardiac monitors currently on the market which focus on arrhythmia detection. Secondly, we are applying our platform technology to create a software tool for detecting heart attacks in the ER environment. This software tool is designed to enable emergency physicians to more accurately and quickly diagnose heart attacks than currently available. Market release of this Product will precede that of the telehealth Product.

To date, we have developed working prototypes for both our telehealth product and our ER product. The ER Product is currently undergoing additional engineering work that we believe will make it ready for FDA 510(k) clearance submission. 

Our focus over next 18 months will be on getting FDA clearances for both of our products and introducing our first Products to the market. We are partnering with Ximedica, a leading medical device design and manufacturing firm, to finalize the development of our initial products to meet all FDA requirements for the 510(k) submission.

(Note: HeartBeam priced its IPO on Nov. 10, 2021, at $6 – the mid-point of its $5.50-to-$6.50 price range – on 2.75 million units, the same number of units in the prospectus, to raise $16.5 million.)